Drugs / Lacosamide
Lacosamide
also known as
LCM · SPM 927 · Vimpat · (r)-lacosamide 1 · [R]-2-acetamido-N-benzyl-3-methoxypropionamide · ADD 243037 · Erlosamide · Lacosamida · +10 more
Other / unclassified targets SCN9A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | MOTPOLY XR | — | 2024-06-07 | fda.gov ↗ |
| Label expansions (6) | US (FDA) | VIMPAT | — | 2014-08-29 – 2023-04-28 | fda.gov ↗ |
| Approved | US (FDA) | VIMPAT | — | 2008-10-28 | fda.gov ↗ |
| Approved | EU (EMA) | Vimpat | — | 2008-08-29 | europa.eu ↗ |
Trials 84 · started per year
today
EU approved 2008
US approved 2008
3
3
1
11
1
2
2
4
3
6
6
6
3
7
4
1
2
2
1
1
2
4
4
3
1
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05788159 | Apr → Jun 2023 | epilepsy | Overseas Pharmaceuticals, Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05603702 | Mar 2023 → Mar 2027 expected | chronic pain syndrome, chronic pancreatitis | Indiana University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03271528 | Apr 2018 → Aug 2020 | alcohol-related disorders | Boston Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01530022 | May 2012 → Jan 2014 | — | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01530386 | Jan → Jul 2012 | — | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01375387 | Mar → Jun 2011 | — | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01450111 | Nov 2008 → Feb 2009 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01796938 | Jun → Nov 2004 | impaired renal function disease | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03186040 | Jul 2017 → Apr 2020 | amyotrophic lateral sclerosis | Chiba University | Completed | No outcome recorded |
| Phase 220 trials | ||||||
| Phase 2 | NCT04519645 | Mar 2021 → Aug 2024 | neonatal epilepsy syndrome | UCB Biopharma SRL | Terminated | No outcome recorded |
| Phase 2 | NCT03897348 | Sep 2018 → Jun 2019 | alcohol-related disorders | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT02342977 | Nov 2014 → Aug 2016 | avascular necrosis, osteoarthritis, rheumatoid arthritis | Indiana University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01969851 | Feb 2014 → Apr 2018 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01724918 | May 2013 → Aug 2016 | focal epilepsy | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded |
| Phase 2 | NCT01458522 | May 2012 → Jul 2014 | epilepsy | Aatif Husain | Completed | No outcome recorded |
| Phase 2 | NCT01118962 | Aug 2010 → Oct 2012 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01118949 | May 2010 → Aug 2011 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00938912 | Dec 2009 → May 2021 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00938431 | Nov 2009 → Aug 2014 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00485472 | Mar → Nov 2007 | osteoarthritis, knee | UCB Pharma | Terminated | No outcome recorded |
| Phase 2 | NCT00440518 | Feb 2007 → Jul 2008 | migraine disorder | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00401830 | Oct 2006 → Feb 2008 | fibromyalgia | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00800215 | Mar → Aug 2004 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00238511 | Nov 2002 → Jan 2005 | postherpetic neuralgia | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00861042 | Apr 2002 → Dec 2004 | diabetic polyneuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00861068 | Feb → Dec 2002 | postherpetic neuralgia | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00552305 | Aug 2001 → Feb 2010 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00861445 | Jun 2001 → Jan 2003 | diabetic polyneuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00237458 | May 2001 → Mar 2011 | neuropathy, painful | UCB Pharma | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT02710890 | May 2017 → Jun 2019 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00151879 | Feb 2005 → May 2006 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2/3 | NCT00235443 | Sep 2004 → Jul 2008 | diabetic neuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 2/3 | NCT00235469 | Apr 2004 → Jun 2005 | diabetic polyneuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 335 trials | ||||||
| Phase 3 | NCT07412132 | Jan 2026 → Jan 2027 expected | bipolar disorder | University of Sao Paulo | Recruiting | No outcome recorded |
| Phase 3 | NCT05632133 | Jun 2022 → Aug 2023 | migraine disorder | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT05851781 | Jun 2022 → Jul 2023 | migraine disorder | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT05291455 | Mar 2022 → Mar 2024 | epilepsy | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05626140 | Sep 2021 → May 2022 | sciatica | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04627285 | Dec 2020 → Feb 2025 | epilepsy | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT02582866 | Jan 2016 → Jan 2020 | epilepsy | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 3 | NCT02408549 | Aug 2015 → Mar 2023 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02477839 | Jun 2015 → May 2020 | focal epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02408523 | Apr 2015 → Apr 2019 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT01911975 | Sep 2014 → May 2017 | neuropathy, small fiber | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01964560 | Aug 2014 → Apr 2022 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02192814 | Jun → Oct 2014 | focal epilepsy | UCB Japan Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02124564 | Apr 2014 → Nov 2017 | focal epilepsy | UCB Japan Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01921205 | Aug 2013 → Jan 2017 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01832038 | Mar 2013 → Jul 2019 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01710657 | Sep 2012 → Jul 2014 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01465997 | May 2012 → Jan 2017 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01484977 | Dec 2011 → Dec 2013 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01345058 | Aug 2011 → Feb 2014 | epilepsy | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01375374 | Jul 2011 → Mar 2013 | focal epilepsy | UCB Pharma | Terminated | No outcome recorded |
| Phase 3 | NCT01243177 | Apr 2011 → Jul 2015 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00655486 | Apr 2008 → Jun 2010 | focal epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00655551 | Apr 2008 → Sep 2009 | focal epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00530855 | Feb 2008 → Dec 2014 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00350103 | Jun 2006 → Jun 2007 | neuropathy, painful | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00220337 | Dec 2004 → Oct 2007 | diabetic polyneuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00515619 | Dec 2004 → Aug 2010 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00135109 | Oct 2004 → Dec 2005 | diabetic neuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00522275 | Oct 2004 → Oct 2009 | focal epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00546351 | May 2004 → Jan 2011 | diabetic polyneuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00220415 | May 2004 → Jan 2006 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00136019 | Mar 2004 → Aug 2006 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00238524 | Dec 2003 → Jan 2005 | diabetic neuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT06866691 | Apr 2025 → Apr 2027 expected | traumatic brain injury | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT06081283 | Nov 2023 → Dec 2024 | brain hypoxia - ischemia, cardiac arrest, intracerebral hemorrhage, traumatic brain injury | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 4 | NCT05969054 | Jul 2023 → Dec 2025 | Alzheimer disease 3, epilepsy | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT05598905 | Oct 2022 → Jan 2024 | respiratory underresponsiveness to hypoxia and hypercapnia | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04144218 | Nov 2019 → Oct 2021 | epilepsy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT02409433 | Aug 2014 → Nov 2015 | epilepsy | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded |
| Phase 4 | NCT01190098 | Aug 2010 → Nov 2014 | focal epilepsy | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01235403 | Jun 2010 → Dec 2011 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 4 | NCT01175954 | May 2010 → Dec 2015 | epilepsy | Evan Fertig | Completed | No outcome recorded |
| Phase 4 | NCT00955357 | Aug 2009 → Apr 2013 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT06549426 | Apr 2025 → Dec 2029 expected | epilepsy | University of Twente | Recruiting | No outcome recorded |
| — | NCT06969417 | Apr → Jul 2025 overdue | herpes zoster, postherpetic neuralgia | CMH Kharian Medical College | Recruiting | No outcome recorded |
| — | NCT01432171 | Jul 2012 → Jun 2017 | malignant glioma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| — | NCT01382017 | Jun 2011 → Aug 2012 | — | University of Kiel | Completed | No outcome recorded |
| — | NCT01110187 | May 2010 → May 2012 | traumatic brain injury | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03559673 | — | focal epilepsy | UCB Biopharma S.P.R.L. | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03436433 Comparator | Jan 2019 → Dec 2020 | brain glioma | Duke University | Terminated | No outcome recorded |
| Phase 2 | NCT03777956 Comparator | Jan 2019 → Jun 2022 | diabetic neuropathy, neuropathy, painful | Danish Pain Research Center | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06243692 Comparator | Feb 2024 → Feb 2025 | migraine disorder | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 3 | NCT02726867 Comparator | Feb 2014 → Nov 2016 | epilepsy | Mid-Atlantic Epilepsy and Sleep Center, LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT01981447 Comparator | Apr 2010 → Aug 2012 | epilepsy | Le Bonheur Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00520741 Comparator | Aug 2007 → Dec 2012 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03607851 Comparator | Aug 2018 → Jun 2019 | focal epilepsy | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00832884 Comparator | Mar 2010 → May 2012 | epilepsy | Le Bonheur Children's Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03636958 Background | Feb 2021 → Jul 2025 | epilepsy | Assistance Publique Hopitaux De Marseille | Withdrawn | No outcome recorded |
Press releases naming this drug 12 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-27 | Daiichi Sankyo | Anti-epilepsy Drug VIMPAT ®, Submission for Supplemental Application for Approval in Japan daiichisankyo.com ↗ |
| 2019-03-25 | Daiichi Sankyo | Anti-epilepsy Drug VIMPAT ® for I.V. infusion 200mg Launched in Japan daiichisankyo.com ↗ |
| 2019-03-11 | Daiichi Sankyo | Anti-epilepsy Drug VIMPAT® Dry syrup 10% Launched in Japan daiichisankyo.com ↗ |
| 2019-01-08 | Daiichi Sankyo | Pediatric Dosage and Administration Approved for Anti-epileptic Drug VIMPAT® Tablets 50 mg and 100 mg daiichisankyo.com ↗ |
| 2017-09-01 | Daiichi Sankyo | Restriction on prescription period lifted for antiepileptic VIMPAT® Tablets 50 mg and 100 mg daiichisankyo.com ↗ |
| 2017-08-25 | Daiichi Sankyo | Antiepileptic VIMPAT® Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients daiichisankyo.com ↗ |
| 2016-08-31 | Daiichi Sankyo | Antiepileptic Drug Vimpat® Tablets 50 mg and 100 mg have been launched. daiichisankyo.com ↗ |
| 2016-08-26 | Daiichi Sankyo | Antiepileptic lacosamide filed for partial amendment of approval to add a new indication in Japan daiichisankyo.com ↗ |
| 2016-07-04 | Daiichi Sankyo | UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT®) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy daiichisankyo.com ↗ |
| 2015-12-21 | Daiichi Sankyo | Results of Analysis of Data from Clinical Trial of Lacosamide (Generic Name) Announced at 2015 Annual Meeting of the American Epilepsy Society daiichisankyo.com ↗ |
| 2015-06-26 | Daiichi Sankyo | Application for Marketing Authorization for Lacosamide (Generic Name) in Japan for the Treatment of Epilepsy daiichisankyo.com ↗ |
| 2014-11-28 | Daiichi Sankyo | UCB and Daiichi Sankyo partner to bring Lacosamide to people living with epilepsy in Japan daiichisankyo.com ↗ |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 99 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lacosamide | “Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin,...” NCT03636958 ↗89“This phase 3 trial is being conducted at approximately 80 sites in the United States (U.S.) to investigate whether lacosamide (SPM 927) at different doses reduces pain in...” NCT00135109 ↗ “The purpose of the study is to evaluate the effectiveness, safety and tolerability of consistent dosages of a study drug (lacosamide [SPM 927]) taken orally twice a day for...” NCT00136019 ↗ “This phase 2b trial is being conducted at approximately 60 sites in the US to investigate whether lacosamide (SPM 927) at different doses reduces pain in subjects with diabetic...” NCT00235469 ↗ “The purpose of this study is to evaluate the effectiveness, safety and tolerability of consistent dosages of study drug (lacosamide) taken orally twice a day for about 4 months.” NCT00220415 ↗ “Lacosamide is a new antiepileptic drug effective for adjunctive treatment of partial-onset seizures.” PMID 20041945 ↗ Dec 2009 “400mg/Day and 600mg/Day SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy” NCT00238524 ↗ “a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)” NCT06549426 ↗ “long-term administration of Lacosamide” NCT00238511 ↗ |
| Known as | (r)-lacosamide 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | [R]-2-acetamido-N-benzyl-3-methoxypropionamide | “Lacosamide ([R]-2-acetamido-N-benzyl-3-methoxypropionamide) belongs to a novel class of functionalized amino acids.” NCT01190098 ↗ |
| Known as | ADD 243037 | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Erlosamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamide accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamide adroiq | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamide cv | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamide extended release tablets | “Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage...” NCT05788159 ↗ |
| Known as | Lacosamide Tablets | “Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than...” NCT05788159 ↗ |
| Known as | Lacosamide ucb | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | LCM | “The primary objective of this Phase 1 crossover study is to evaluate the neuropsychological effects of Lacosamide (LCM) compared to Carbamazepine Immediate Release (CBZ-IR)...” NCT01530022 ↗7“continued access to Lacosamide (LCM) for monotherapy use” NCT03559673 ↗ “lacosamide (LCM) added to levetiracetam (LEV)” PMID 27714769 ↗ Oct 2016 “Strength: Lacosamide (LCM) 50 mg, LCM 100 mg” NCT01832038 ↗ “start dose Lacosamide (LCM) is 100 mg/day” NCT01375374 ↗ “lacosamide (LCM)” NCT01382017 ↗ “Lacosamide (LCM)” NCT01243177 ↗ |
| Known as | Motpoly | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Motpoly xr | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | SPM 927 | “Each patient who qualifies and chooses to participate in the study will receive placebo (inactive drug) or gradually increasing doses of lacosamide (SPM 927) up to the target...” NCT00220415 ↗6“The purpose of the study is to evaluate the effectiveness, safety and tolerability of consistent dosages of a study drug (lacosamide [SPM 927]) taken orally twice a day for...” NCT00136019 ↗ “400mg/Day and 600mg/Day SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy” NCT00238524 ↗ “Oral SPM 927” NCT00238511 ↗ |
| Known as | SPM 929 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00350103 ↗ |
| Known as | SPM927 / Lacosamide / Vimpat | “SPM927 / Lacosamide / Vimpat®” NCT00861042 ↗ |
| Known as | Vimpat | “The purpose of this study is to investigate the impact of the anti-seizure medication Lacosamide (Vimpat®) on sleep and wakefulness in adults with focal (partial onset) seizures.” NCT01190098 ↗3“INTERVENTION: Four- to six-week Titration Phase followed by 12-week maintenance treatment with adjunctive lacosamide (Vimpat®) [200, 400 or 600 mg/day] or placebo.” PMID 21090839 ↗ Dec 2010 “Lacosamide, Vimpat®” NCT00861068 ↗ “Lacosamide, Vimpat®” NCT00861445 ↗ |
| Action | Inhibit | “This mechanism of action results in stabilization of hyperexcitable neuronal membranes, inhibition of neuronal firing, and reduction in long-term channel availability without...” PMID 23859801 ↗ Jul 2013 |
| Modality | Other / unclassified | “belongs to a novel class of functionalized amino acids.” NCT01190098 ↗ |
| Route | Oral | “The efficacy and tolerability of oral lacosamide (200, 400, and 600 mg/day) was evaluated in patients with painful diabetic neuropathy” PMID 19409861 ↗ May 2009 |
| Target | SCN9A | “The finding of voltage-gated sodium channel mutations in small fibre neuropathy (with mutations in SCN9A, encoding for Nav1.7) being most frequently reported suggest a specific...” PMID 30649227 ↗ Feb 2019 |